Your session is about to expire
What is Rinvoq
UpadacitinibThe Generic name of this drug
Treatment SummaryUpadacitinib is a medication used to treat rheumatoid arthritis, an autoimmune disease that causes inflammation in the joints. It works by blocking a protein known as Janus kinase (JAK) 1, which is believed to be involved in the body's immune response. Upadacitinib is taken orally and was approved by the FDA in 2019. It is marketed under the brand name RINVOQ™ and is also being studied to see if it can help treat other inflammatory conditions such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and at
Rinvoqis the brand name
Rinvoq Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rinvoq
Upadacitinib
2019
3
Approved as Treatment by the FDA
Upadacitinib, also known as Rinvoq, is approved by the FDA for 6 uses like inadequate response to other therapeutic measures and Rheumatoid Arthritis .inadequate response to other therapeutic measures
Used in combination with Halcinonide to help manage inadequate response to other therapeutic measures
Rheumatoid Arthritis
Used to treat Moderately to Severely Active Rheumatoid Arthritis in combination with Methotrexate
Dermatitis, Atopic
Used in combination with Halcinonide to help manage moderate, refractory Atopic dermatitis
Dermatitis, Atopic
Used in combination with Halcinonide to help manage refractory, severe Atopic Dermatitis
Ankylosing Spondylitis
Used in combination with Ketorolac to help manage Ankylosing Spondylitis (AS)
inadequate response or intolerance to DMARDs
Used in combination with Ketorolac to help manage inadequate response or intolerance to DMARDs
Effectiveness
How Rinvoq Affects PatientsUpadacitinib is a drug used to treat autoimmune inflammatory conditions such as rheumatoid arthritis. It works by blocking Janus Kinases, which are cell signals that trigger inflammation. In clinical studies, upadacitinib reduced inflammation-causing interleukins, increased the number of lymphocytes in the body, and slightly decreased levels of immunoglobulins.
How Rinvoq works in the bodyRheumatoid arthritis is a chronic autoimmune disorder caused by the interaction between immune cells and inflammatory chemicals. Janus Kinase (JAK) proteins are involved in this process by helping certain inflammatory chemicals activate their receptors. Upadacitinib blocks JAK proteins and stops these chemicals from causing inflammation. In studies, it was shown to stop the inflammation caused by chemicals like IL-6 and IL-7. By blocking JAK proteins, Upadacitinib prevents inflammation from developing in people with rheumatoid arthritis.
When to interrupt dosage
The advised dosage of Rinvoq is contingent upon the determined condition, for example Arthritis, Psoriatic, methotrexate and inadequate response to conventional therapy. The amount of dosage is contingent upon the technique of delivery featured in the table beneath.Condition
Dosage
Administration
Moderately to Severely Active Ulcerative Colitis
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Rheumatoid Arthritis
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Tumor Necrosis Factor Inhibitors
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
candidate for systemic therapy
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
inadequate response to other therapeutic measures
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Ankylosing Spondylitis
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
inadequate response to conventional therapy
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
inadequate response or intolerance to DMARDs
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Warnings
Rinvoq ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Upadacitinib may interact with Pulse Frequency
Common Rinvoq Drug Interactions
Drug Name
Risk Level
Description
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Upadacitinib.
Bleselumab
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Bleselumab.
Cyclosporine
Major
Upadacitinib may increase the immunosuppressive activities of Cyclosporine.
Fasitibant
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Fasitibant.
Inolimomab
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Inolimomab.
Rinvoq Toxicity & Overdose RiskTaking too much upacitinib can cause adverse reactions, so it is important to monitor for signs and symptoms if an overdose occurs. It has been found that rats have a toxic dose of 14500mg/kg when given upacitinib orally.
Rinvoq Novel Uses: Which Conditions Have a Clinical Trial Featuring Rinvoq?
At present, there are 3 clinical trials assessing the capability of Rinvoq in providing relief from Methotrexate, Atopic Dermatitis and Ankylosing Spondylitis.Condition
Clinical Trials
Trial Phases
Dermatitis, Atopic
0 Actively Recruiting
inadequate response to conventional therapy
0 Actively Recruiting
Moderately to Severely Active Ulcerative Colitis
0 Actively Recruiting
Tumor Necrosis Factor Inhibitors
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
Ankylosing Spondylitis
2 Actively Recruiting
Phase 3, Not Applicable
inadequate response or intolerance to DMARDs
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
candidate for systemic therapy
0 Actively Recruiting
Rinvoq Reviews: What are patients saying about Rinvoq?
5Patient Review
10/2/2021 Rinvoq has completely changed my quality of life for the better. I was struggling with pain from RA and PsA, and nothing was helping me. But this medication has reduced my pain by 90%. The only downside is some intestinal issues, but that has stabilized now.
5Patient Review
8/3/2021 I'm feeling a lot better since starting this medication, though I am more tired than usual and have noticed some bruising.
5Patient Review
6/4/2021 Rinvoq is my favorite medication. It really helps in the morning.
5Patient Review
5/31/2022 I noticed a difference in my skin after taking the first pill, and it continued to improve over the next few weeks. My eczema was severe before starting this medication, but it has helped immensely.
5Patient Review
7/31/2021 I don't know why my previous five-star review was changed to four stars, but I'm reposting this with the full rating.
4.7Patient Review
3/1/2022 I started on Rinvoq in late July 2019 and noticed a significant decrease in fatigue within just a few weeks! By three months, my inflammation factor was within normal ranges. I stopped for five weeks after total knee replacement surgery in August 2020 and again for Covid in January 2021 and January 2022. The only issue I have is the scalp acne that runs on a 4-5 week schedule. It is constantly cycling! My rheumatologist monitors my lab factors which include blood counts.
3.7Patient Review
6/12/2022 I had a stroke while taking this medication, which is now accompanied by a black box warning. I was none of the risk factors typically associated with such an event (i.e. over 50 years old, pre-existing conditions, etc.), so please be extra careful when considering Rinvoq.
3.3Patient Review
6/13/2022 Though this medication did help with my joint pain, the side effects were too much for me to handle. I saw acne, fatigue, and depression within days of starting the medication. I stopped taking it after a month, and though my acne cleared up relatively quickly, my mood has not stabilized and I am still struggling with low energy levels.
3.3Patient Review
10/17/2022 I experienced anger problems, upper-tract infection, infections all over my body, diarrhea, lots of headaches and tiredness while taking this drug. I also had mild hallucinations at times (waving walls).
2.7Patient Review
2/18/2022 This caused me to have severe neutropenia, which is a condition where the body doesn't produce enough white blood cells.
2.3Patient Review
8/9/2021 Unfortunately, this medication made me very ill on two separate occasions. I had high hopes it would help my RA, but instead it caused me severe chest and stomach pains. I wouldn't recommend it to anyone.
2.3Patient Review
2/8/2022 So far, this treatment has made me feel worse in a number of ways. I'm incredibly tired to the point of falling asleep during the day, my muscles hurt more, and I've been experiencing joint pain, headaches, and acne.
Patient Q&A Section about rinvoq
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Rinvoq a high risk medication?
"The FDA has issued warnings about serious side effects associated with Rinvoq, including infections, cancer, blood clots, cardiovascular problems, and increased risk of death."
Answered by AI
What is Rinvoq used to treat?
"The drug RINVOQ is used to treat moderate to severe rheumatoid arthritis in adults who have not responded well or are unable to tolerate other drugs known as tumor necrosis factor (TNF) blockers."
Answered by AI
Is Rinvoq and Humira the same?
"The ICER states that Rinvoq provides a small to substantial health benefit over Humira with a value-based price benchmark of $44,000 to $45,000 per year of treatment."
Answered by AI
Does Rinvoq have side effects?
"If you experience any of the following symptoms, you may be having an allergic reaction: rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat. Some of these reactions can be serious."
Answered by AI